Evaluation of plasma and tissue s100a4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 475-485

  Yang, H ^a   Zhao, K ^b   Yu, Q ^b   Wang, X ^b   Song, Y ^a   Li, R ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Calcium binding protein S100A4; Clear cell renal cell carcinoma (CCRCC); Metastasis; Survival; Vascular endothelial growth factor (VEGF)

Indexed keywords

CALVASCULIN; MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; UPREGULATION;

EID: 84860450602     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000209     Document Type: Article

References (36)

1. Li L, Kaelin WG Jr: New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 667-686.
2. Strohmeyer T, Ackermann R: Classic and modern prognostic indicators in renal cell carcinoma. Review of the literature. Urol Int 1991; 47: 203-212.
3. Nagashima Y, Inayama Y, Kato Y, et al: Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004; 54: 377-386.
4. Valladares Ayerbes M, Aparicio Gallego G, Díaz Prado S, et al: Origin of renal cell carcinomas. Clin Transl Oncol 2008; 10: 697-712.
5. Garrett SC, Varney KM, Weber DJ, et al: S100A4, a mediator of metastasis. J Biol Chem 2006; 281: 677-680.
6. Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010; 176: 528-535.
7. Helfman DM, Kim EJ, Lukanidin E, et al: The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005; 92: 1955-1958.
8. Tarabykina S, Griffiths TR, Tulchinsky E, et al: Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 2007; 7: 217-228.
9. Rosty C: Towards the identification of new markers of pancreatic cancer by gene expression analysis. Bull Cancer 2004; 91: 593-598 [in French, English abstract].
10. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(suppl 1): 2-10.
11. Golshayan AR, Brick AJ, Choueiri TK: Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol 2008; 4: 85-92.
12. Botelho F, Pina F, Lunet N: VEGF and prostatic cancer: a systematic review. Eur J Cancer Prev 2010; 19: 385-392.
13. Moran MS, Yang Q, Goyal S, et al: Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast- conserving therapy. Int J Radiat Oncol Biol Phys 2011; 81: 1236-1243.
14. George S, Bukowski RM: Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 2007; 7: 1737-1747.
15. Nieder C, Andratschke N, Jeremic B, et al: Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 2003; 23: 5117-5123.
16. Dorff TB, Goldkorn A, Quinn DI: Targeted therapy in renal cancer. Ther Adv Med Oncol 2009; 1: 183-205.
17. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
18. Gordon MS: Novel antiangiogenic therapies for renal cell cancer. Clin Cancer Res 2004; 10: 6377S-6381S.
19. Ai KX, Lu LY, Huang XY, et al: Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol 2008; 14: 1931-1935.
20. Fleming ID, American Joint Committee on Cancer, American Cancer Society, et al: Kidney. In: AJCC Cancer Staging Manual, 5th edn (Fleming ID, ed). Philadelphia: Lippincott-Raven, 1997; pp 231-239.
21. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663.
22. Zou M, Al-Baradie RS, Al-Hindi H, et al: S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 2005; 93: 1277-1284.
23. Bièche I, Olivi M, Champème MH, et al: Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer 1998; 78: 661-666.
24. Rosivatz E, Becker I, Specht K, et al: Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
25. Mazzucchelli L: Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002; 160: 7-13.
26. Marenholz I, Lovering RC, Heizmann CW: An update of the S100 nomenclature. Biochim Biophys Acta 2006; 1763: 1282-1283.
27. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540-551.
28. Schneider M, Hansen JL, Sheikh SP: S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl) 2008; 86: 507-522.
29. Rudland PS, Platt-Higgins A, Renshaw C, et al: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000; 60: 1595-1603.
30. de Silva Rudland S, Martin L, Roshanlall C, et al: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006; 12: 1192-1200.
31. Lee WY, Su WC, Lin PW, et al: Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004; 66: 429-438.
32. Pedersen KB, Nesland JM, Fodstad Ø, et al: Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies. Br J Cancer 2002; 87: 1281-1286.
33. Heizmann CW, Allard D, Birchmeier W, et al: The metastasis-associated gene S100A4 is a novel target of β-catenin/T-cell factor signaling in colon cancer. Gastroenterology 2006; 131: 1486-1500.
34. Flatmark K, Maelandsmo GM, Mikalsen SO, et al: Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 2004; 25: 31-40.
35. Ambartsumian N, Klingelhöfer J, Grigorian M, et al: The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001; 20: 4685-4695.
36. Rini BI: Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13: 1098-1106.